News - Medical and health professional investment - VC and PE investment business - Shenzhen Efung Investment Management Co. Ltd.

发布时间: 2025 - 10 - 23

CoreRay’s 3 Key Products Secure EU CE Certification

Recently, three core interventional access products independently developed by CoreRay Medical have successfully obtained EU CE certification:Zhipeng Single-use Interventional MicrocatheterZhiguan Peripheral Vascular Microguide WireRuishen Balloon Dilatation CatheterThis marks CoreRay’s first EU CE certification since its founding, signifying international authoritative recognition of its R&D capabilities and quality system, and laying a solid foundation for entering the European and global markets.EU CE certification is a globally recognized gold standard for medical device safety and per...

浏览次数：1

查看详情>>

发布时间: 2025 - 10 - 22

Huayuan Wins "Maker in China" Innovation Award! Its Subsidiary Huajin Bio Wins Third Prize

On October 21, 2025, the 10th "Maker in China" Shenzhen SME Innovation and Entrepreneurship Competition successfully concluded. Huayuan Regenerative Medicine Co., Ltd., an Efung Capital portfolio company, stood out among numerous participating enterprises with its "Implantable Bioartificial Organ Development" project and won the Innovation Award of the competition.Its subsidiary, Huajin Bio, won the Third Prize with its "Human Kidney Organoid Modeling and Translational Research Platform Based on Stem Cells" project.The "Maker in China" SME Innovation and...

浏览次数：1

查看详情>>

发布时间: 2025 - 10 - 20

Beixin Life and Ying Minda Selected as National Key "Little Giant" Enterprises

Recently, the list of the second batch of new key "Little Giant" enterprises, evaluated by the Ministry of Finance and the Ministry of Industry and Information Technology, was announced. Beixin Life and Ying Minda, portfolio companies of Efung Capital, were successfully selected for the list due to their exceptional innovation capabilities and deep technological, joining the ranks of nationally supported key "Little Giant" enterprises.Key "Little Giant" enterprises are selectively chosen from those already recognized as specialized and sophisticated "Little G...

浏览次数：1

查看详情>>

发布时间: 2025 - 10 - 17

Cell Publishes Xunlu Bio's BCMA CAR-T Research for Multiple Sclerosis

On October 16, 2025, Xunlu Bio announced that the internationally top-tier academic journal Cell published online the research results of its self-developed fully human BCMA-targeted CAR-T cell therapy, Equecabtagene Autoleucel, for the treatment of progressive multiple sclerosis (PMS). This study not only demonstrates, for the first time globally, the safety and efficacy of CAR-T cell therapy in treating progressive multiple sclerosis but also represents the first publication in Cell of research results on successful treatment of autoimmune diseases with BCMA-targeted CAR-...

浏览次数：1

查看详情>>